Table 6 Meta-analyses of studies of specific myeloid maligancy type for benzene.*
Characteristics | No. of estimates | Meta-RR estimate (95%CI) | I2 test (%) | p-value | Egger’s test |
|---|---|---|---|---|---|
ML | |||||
Overall | 7 | 1.56 (1.10–2.20) | 45.06 | 0.0114 | 0.0063** |
High exposure | 4 | 1.28 (0.87–1.88) | 40.98 | 0.2051 | 0.0984 |
Low exposure | 1 | 2.24 (0.65–7.71) | NA | 0.2012 | NA |
Any exposure | 2 | 2.15 (1.29–3.58) | 0.00 | 0.0033 | NA |
Study type | |||||
Case-control studies | 0 | NA | |||
Cohort studies | 7 | 1.56 (1.10–2.20) | 45.06 | 0.0114 | 0.0063** |
AML | |||||
Overall | 27 | 1.30 (1.09–1.55) | 48.91 | 0.0037 | 0.0155** |
High exposure | 8 | 1.65 (1.13–2.41) | 46.97 | 0.0100 | 0.1176 |
Low exposure | 5 | 1.54 (0.89–2.66) | 58.71 | 0.1248 | 0.2679 |
Any exposure | 14 | 1.14 (0.93–1.39) | 36.29 | 0.2057 | 0.3933 |
Study type | |||||
Case-control studies | 9 | 1.34 (1.03–1.75) | 40.12 | 0.0281 | 0.5929 |
Cohort studies | 18 | 1.29 (1.02–1.63) | 51.98 | 0.0364 | 0.0119** |
CML | |||||
Overall | 18 | 1.25 (1.00–1.55) | 0.00 | 0.0456 | 0.2347 |
High exposure | 3 | 2.79 (1.44–5.40) | 0.00 | 0.0024 | 0.7110 |
Low exposure | 2 | 1.93 (0.64–5.82) | 0.00 | 0.2447 | NA |
Any exposure | 13 | 1.11 (0.87–1.40) | 0.00 | 0.4019 | 0.4132 |
Study type | |||||
Case-control studies | 5 | 1.93 (1.05–3.56) | 25.76 | 0.0353 | 0.6999 |
Cohort studies | 13 | 1.13 (0.89–1.45) | 0.00 | 0.3215 | 0.3540 |
MDS | |||||
Overall | 9 | 1.87 (1.39–2.52) | 40.73 | < 0.0001 | 0.0560 |
High exposure | 6 | 1.80 (1.18–2.75) | 51.97 | 0.0065 | 0.1173 |
Low exposure | 2 | 2.29 (1.51–3.48) | 0.00 | < 0.0001 | NA |
Any exposure | 1 | 1.64 (0.83–3.22) | N/A | 0.1510 | NA |
Study type | |||||
Case-control studies | 5 | 1.85 (1.28–2.67) | 33.43 | 0.0012 | 0.5538 |
Cohort studies | 4 | 1.94 (1.19–3.18) | 43.78 | 0.0081 | 0.1088 |